StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.95 | $0.95 | -0.23% | 1.1M |
| 05-12 | $0.80 | $0.53 | -33.73% | 12.3M |
| 05-13 | $0.54 | $0.40 | -27.09% | 13.3M |
| 05-14 | $0.42 | $0.56 | +34.30% | 13.9M |
| 05-15 | $0.58 | $0.50 | -13.10% | 3.5M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $190.00K | $190.00K | $0.00 | $0.00 |
Operating Income | $-77.63M | $-62.83M | $-36.09M | $-15.77M |
Net Income | $-74.12M | $-60.16M | $-34.41M | $-14.88M |
EPS (Diluted) | $-0.80 | $-0.66 | $-0.39 | $-0.17 |
Total Assets | $93.00M | $106.65M | $101.53M | $97.25M |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $10.74M | $6.15M | $17.22M | $10.36M |
Free Cash Flow OCF − CapEx | $-62.06M | $-49.84M | $-29.32M | $-15.42M |
Shares Outstanding | 98.03M | 97.99M | 92.87M | 89.00M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).